Zimmer Features Trabecular Metal(TM) Augment Shapes and Cones for Knee Revision Surgery at EFORT Congress

COPENHAGEN, Denmark, June 2, 2011 -

Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in
musculoskeletal care, is featuring a new, comprehensive range of Trabecular
Metal Material augment shapes and cones for use in knee revision surgeries at
the 12th annual European Federation of National Associations of Orthopaedics
and Traumatology (EFORT) meeting in Copenhagen, Denmark.

During revision surgeries, surgeons are often faced with a range of small
to large cavitary bone defects. The new augments are designed to fill these
defects, provide a structural foundation to the existing bone and help
support revision knee implants.

Trabecular Metal Tibial and Femoral Cone Augments have the potential to
provide reliable structural replacement of bone and stable fixation for
femoral and tibial articulating components in even challenging knee revision
cases. Designed to treat deficiencies in the knee independent of the final
implant position, the tapered shape of the augments fits the patient's
anatomy without influencing implant alignment. The new augments are designed
for use with the NexGen(R) Knee System.

"The launch of this fully-instrumented range of revision knee cones
reinforces Zimmer's commitment to providing surgeons with the most
comprehensive array of solutions to confidently approach knee revisions with
the NexGen Knee System," said Jeffery A. McCaulley, President, Zimmer
Reconstructive. "The broad range of anatomic sizing options now available
allows surgeons to more accurately position implants and fill defects in
almost all kinds of knee revision cases."

The augments are constructed from Zimmer's Trabecular Metal Material, a
highly porous biomaterial that resembles the structure, function and
physiology of trabecular bone. No other porous metal material is supported by
the amount of peer-reviewed, published clinical data of Trabecular Metal
Technology and its history of clinical success in orthopaedic applications.
This novel material supports bone formation, enabling biologic fixation and a
stiffness similar to cancellous bone. The elasticity of Trabecular Metal
Technology provides more normal physiological loading which has the potential
to decrease stress shielding and improve long-term implant fixation.

For more information, visit the Zimmer booth at EFORT or go to
www.zimmer.com.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs,
develops, manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical products. Zimmer has
operations in more than 25 countries around the world and sells products in
more than 100 countries. Zimmer's 2010 sales were approximately $4.2 billion.
The Company is supported by the efforts of more than 8,000 employees
worldwide.

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995
based on current expectations, estimates, forecasts and projections about the
orthopaedics industry, management's beliefs and assumptions made by
management. Forward-looking statements may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "assumes," "guides,"
"targets," "forecasts," and "seeks" or the negative of such terms or other
variations on such terms or comparable terminology. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that could cause actual outcomes and results to differ
materially. For a list and description of such risks and uncertainties, see
our periodic reports filed with the U.S. Securities and Exchange Commission.
We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be set forth in our periodic reports.
Readers of this document are cautioned not to place undue reliance on these
forward-looking statements, since, while we believe the assumptions on which
the forward-looking statements are based are reasonable, there can be no
assurance that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

Media: Garry R. Clark, +1-574-372-4493, garry.clark at zimmer.com; or Investors: Robert J. Marshall Jr., +1-574-371-8042, robert.marshall. at zimmer.com